CTOs on the Move

Nipro Medical

www.nipro.com

 
Nipro provides premium renal medical devices, including dialyzers, bloodlines, AVF needles, as well as high-quality medical surgical products.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.nipro.com
  • 200, Crossing Blvd
    Bridgewater, NJ USA 08807
  • Phone: 908.393.7030

Executives

Name Title Contact Details

Similar Companies

Sirnaomics

Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology.

Morris and Dickson Co.

Morris and Dickson Co. is a Shreveport, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Takeda

For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Our mission is simple: we strive toward better health for patients worldwide through leading innovation in medicine. This mission: • Drives our research and development of prescription drugs • Promotes our commitment to social responsibility • Marks our growth and success At Takeda, our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world. Our robust product pipeline is focused on treating serious diseases and disorders, including bone and joint disorders, cardiovascular disease, central nervous system disorders, chronic kidney disease, diabetes, gastroenterology, gynecological disorders and infectious disease.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.